[Therapeutic use of a gonadotropin releasing hormone analogue in breast cancer].
Superagonistic analogues of Gn-RH given chronically produce a paradoxic inhibition of pituitary gonadotropin secretion and consequently decrease the peripheric hormones estradiol and progesterone to a postmenopausal level. For curative purposes buserelin (SuprefactR, Hoechst) treatment has been performed by the authors in two cases of breast cancer. The patients--one with NED (no evidence of disease) and the other with pulmonary and osseal metastases--in addition to low hormonal levels developed amenorrhoea. A group of climacteric complaints were observed without any toxic side effects, however. The treatment of premenopausal women suffering from breast cancer with chronic administration of Gn-RH analogues may constitute a valuable alternative to surgical oophorectomy.
Kahán
Z
Z
Radiológiai Klinika, Szent-Györgyi Albert Orvostudományi Egyetem, Szeged.
Falkay
G
G
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use*; D004967:Estrogens / Q000032:analysis; D005260:Female; D006062:Gonadotropins / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D010906:Pituitary Hormone-Releasing Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D011374:Progesterone / Q000032:analysis
D004967:Estrogens; D006062:Gonadotropins; D010906:Pituitary Hormone-Releasing Hormones; D011374:Progesterone; D002064:Buserelin
Gonadotrop releasing hormon (Gn-RH) analóg alkalmazása emlörák betegségben.